White label ELPA - ClinicalTrials.eu

Study on Mepolizumab and Surgery for Patients with Chronic Rhinosinusitis with Nasal Polyps

Recruiting

3 1 1 1
Investigated diseases:
- Chronic rhinosinusitis with nasal polyps
Investigated drugs:
- Mepolizumab
Comparison of dapagliflozin versus metformin treatment in patients with early stage type 2 diabetes to evaluate survival and complications

Recruiting

3 1 1 1
Investigated drugs:
- Dapagliflozin Propanediol
Study on Amantadine for Reducing Motor Fluctuations in Advanced Parkinson’s Disease Patients

Recruiting

2 1 1
Investigated diseases:
- Parkinson’s disease
Investigated drugs:
- Amantadine Hydrochloride
Study on Dapagliflozin for Patients with Chronic Right Heart Failure

Recruiting

2 1 1
Investigated diseases:
- Cardiac failure chronic
Investigated drugs:
- Dapagliflozin
Study on the Effects of Atezolizumab, Bevacizumab, Oxaliplatin, and Capecitabine in Patients with Colorectal Cancer and Liver Metastasis

Recruiting

2 1 1 1
Investigated diseases:
Investigated drugs:
Study on Senicapoc for Patients with Progressive Fibrotic Interstitial Lung Disease to Prevent Disease Progression

Recruiting

2 1 1
Investigated diseases:
- Interstitial lung disease
Investigated drugs:
- Senicapoc
- Placebo
Study on Preserving the Rectum in Early-Stage Rectal Cancer Patients Using Oxaliplatin and Capecitabine with Radiation Therapy

Recruiting

2 1 1 1
Investigated diseases:
- Rectal cancer
Investigated drugs:
- Capecitabine
- Oxaliplatin
Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Recruiting

3 1 1 1
Investigated diseases:
Investigated drugs:
+5
Study on Bezafibrate for Patients with Primary Biliary Cholangitis Not Responding Well to Ursodeoxycholic Acid

Recruiting

3 1 1
Investigated diseases:
- Primary biliary cholangitis
Investigated drugs:
- Bezafibrate
Study of EGL-001 for Adults with Advanced or Metastatic Solid Tumors

Recruiting

1 1 1 1
Investigated diseases:
- Neoplasm
Investigated drugs:
- Egl-001
- Pembrolizumab

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies